Comparative Pharmacology
Head-to-head clinical analysis: ALEVE versus IBU TAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE versus IBU TAB.
ALEVE vs IBU-TAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
2-4 hours (terminal elimination half-life); in overdose or hepatic impairment, may be prolonged to >4 hours. Clinically, the short half-life supports dosing every 6-8 hours for acute pain.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Renal excretion of conjugated metabolites (approximately 90% of an administered dose) with less than 1% excreted unchanged. Biliary/fecal elimination accounts for less than 5%.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)